Since August, a large number of pharmaceutical companies have issued announcements of increasing their shareholdings, involving Yahuilong, Xinbang Pharmaceutical, Haier Bio, Kangtai Bio and other pharmaceutical companies
.
Yahuilong: The concerted action of the actual controller increases the shareholding through the contractual fund
Yahuilong: The concerted action of the actual controller increases the shareholding through the contractual fund
On August 4th, Yahuilong announced that the company received a notice from Mr.
Hu Deming, the person acting in concert with Mr.
Hu Kunhui, the company's actual controller, and learned that Mr.
Hu Deming, through the contractual fund Shuofeng Changjiang No.
2,286,627 shares of the company will be increased through centralized bidding through the Shanghai Stock Exchange trading system, and it is planned to trade through the Shanghai Stock Exchange at a price not higher than 35 yuan per share within 6 months from August 2, 2022.
The system will continue to increase its holdings of the company's shares by means of centralized bidding or block transactions as permitted by law.
The cumulative increase (including this time) is not less than RMB 150 million and not more than RMB 280 million
.
Haier Bio: The concerted action of the actual controller increases the shareholding
Haier Bio: The concerted action of the actual controller increases the shareholding
Haier Biology announced on August 6 that Qingdao Haichuangzhi Management Consulting Enterprise (Limited Partnership), the company's actual controller, Haier Group Corporation, acting in concert, plans to trade through the Shanghai Stock Exchange within 6 months from July 27, 2022 The system increases the company's shares through centralized bidding, and the cumulative increase (including this time) is not less than 25 million yuan and not more than 50 million yuan (hereinafter referred to as "this time increase")
.
No price range is set for this increase
.
As of August 4, 2022, Haichuangzhi has increased its holdings of 742,855 shares of the company through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.
23% of the company's total share capital, with an increase of RMB 50.
0318 million.
Implemented
.
Kangtai Bio: Company directors and senior executives increase their holdings of the company's shares
Kangtai Bio: Company directors and senior executives increase their holdings of the company's shares
Kangtai Bio announced on the evening of August 1 that the company's controlling shareholder, actual controller, chairman Mr.
Du Weimin, vice chairman and vice president Mr.
Zheng Haifa, vice chairman Mr.
Wen Feidong, director and president Mr.
Miao Xiang, director and vice president Mr.
Liu Jiankai , Chief Financial Officer Ms.
Zhou Hui, and Secretary of the Board of Directors Ms.
Tao Jin plan to conduct centralized bidding transactions, block transactions within 6 months from the date of disclosure of this announcement (except for the period when laws, regulations, normative documents and other relevant regulations are not allowed to increase holdings).
Increase the company's shares by means of other means permitted by laws and regulations, and the estimated increase in holdings shall not be less than RMB 45 million
.
Xinbang Pharmaceutical: Senior executives increase their stake in the company
Xinbang Pharmaceutical: Senior executives increase their stake in the company
Xinbang Pharmaceutical announced on August 4 that Mr.
Gao Wenlin, a senior executive of the company, plans to increase his shareholding in the company by means of block transactions or centralized bidding within five months from May 20, 2022, with a cumulative increase of not less than 1,000.
million
.
As of August 3, 2022, the holding time of this holding increase plan has passed halfway, and Mr.
Gao Wenlin increased his holdings through the centralized bidding transaction method of the Shenzhen Stock Exchange trading system from May 20, 2022 to August 3, 2022.
There are 1,018,700 shares of the company, accounting for 0.
0503% of the company's total share capital, and the cumulative increase is 5,008,093 yuan
.
Epilogue
Epilogue
According to the industry, the increase in holdings is due to the continued bullishness on a certain stock, and the behavior of continuing to buy more when the price of the stock falls or rises
.
For pharmaceutical companies, executives' increased shareholding is generally based on their confidence in the company's future sustainable development prospects and recognition of the company's long-term investment value
.
